NOS3 and pulmonary hypertension: A Phase I clinical trial, PHACeT (Pulmonary Hypertension Assessment of Cell Therapy) is currently under way to confirm tolerability, safety, and efficacy of autologous endothelial progenitor cells programmed to overexpress the endothelial nitric oxide synthase [98].